Viriom’s lead drug - Elpida® (elsulfavirine 20 mg) once daily capsules is a prescription medicine used with other HIV-1 medicines to treat HIV-1 infection. Elsulfavirine (ESV) is the pro-drug of the active compound VM1500A (RO4970335), a potent, highly selective NNRTI which obtained market authorization in Russia and is in the process of obtaining new drug authorizations in multiple global markets. Its antiviral profile is superior to all currently marketed NNRTIs.

In 2009 Viriom licensed a family of patents and drug candidates which gave rise to Elpida® and VM1500A from F. Hoffmann-La Roche. In 2017 Viriom obtained the first market authorization for Elpida® (elsulfavirine) 20 mg-based daily treatment in Russia and EurAsEC countries. Viriom continues to expand registration and commercialization of therapies and preventive medicines with regional and global partners in developing and developed global markets.

Clinical studies completed to date confirmed excellent tolerability, favorable safety profile and high efficacy of Elpida®. The 48 and 96 week clinical studies confirmed that elsulfavirine 20 mg-based daily regimen in combination with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) was equally efficacious as efavirenz (EFV) 600 mg-based therapy, but significantly better tolerated, safer and more stable to drug-resistant mutations.

Based on the drug’s favorable pharmacokinetics, Viriom is developing elsulfavirine’s oral less frequent (weekly) dosing regimen for treatment of HIV1. Viriom has advanced the clinical development of an oral weekly dosing of elsulfavirine as Pre- and Post-Exposure Prophylaxis (PrEP and PEP). Elpida® does not cure HIV-1 infection or AIDS.

Agape® FDC (20mg ESV+200mg TDF+300mg FTC) once daily tablet has been approved for marketing in Russia and EurAsEC countries in 2022.

Depulfavirine is a nanosphere drug for once-monthly or less frequent use in combination therapy.

Viriom is developing a long-acting injectable formulation of VM3500 – a novel Integrase Strand Transfer Inhibitor (INSTI) as a component of combination treatment for HIV-1 infection.

Viriom is building high potency drug combinations for treatment of SARS-CoV-2 infection and COVID19 disease. Our portfolio focuses on a range of therapeutic options from treating soon after infection in symptomatic or asymptomatic individuals, to providing new treatments for persons with moderate to severe disease. Viriom is actively engaged in developing prophylactic treatments to prevent SARS-CoV-2 infection among high-risk individuals and health care workers. Programs for SARS-CoV-2 therapy include clinical and near-term clinical assets and objectives.

Viriom recognizes the risk to public health posed by seasonal and pandemic influenza viruses and the need for new therapies. We are developing a targeted, potent therapeutic for treating influenza and advancing this drug to human clinical trials (AV5124). Viriom is developing combination therapies that will overcome the problem of drug-resistant influenza while having increased potency and greater safety. Novel combinations have been developed and are advancing through preclinical evaluation.

Quisinostat is a novel selective oral, highly-potent pan-histone deacetylase (HDAC1) inhibitor. It amplifies HDAC-repressed expression of E-cadherin, leading to a reversal of epithelial to mesenchymal transition (EMT). The latter is associated with platinum-based chemotherapy resistance. Clinical trials to date have indicated acceptable safety and promissing potential of quisinostat againast platinum-resistant ovarian cancer in combination with paclitaxel and carboplatin.

Viriom is supporting new indications for quisinostat in combination with standard of care or other experimental agents, i.e., translocation-associated sarcomas in adolescents and young adults, uveal melanoma, combination with immunomodulator treatments to increase efficacy in solid tumors, i.e., gynecologic cancers, lung cancer.